Yttrium-86
A PET-visible radioactive stand-in for the treatment isotope yttrium-90, used to see in advance, on a scan, exactly where a yttrium-90 therapy dose would go and how much radiation each organ would receive.
Overview
Yttrium-90, used for radioembolisation (TARE/SIRT) and older radioimmunotherapy agents, is a pure beta emitter with no directly imageable gamma or positron emission, which makes patient-specific pre-therapy dosimetry difficult. Yttrium-86 solves that problem: it is chemically identical to yttrium-90, so an 86Y-labelled version of the same antibody, peptide or microsphere construct has an identical biodistribution, and its 14.7-hour half-life with about 33% positron emission allows PET imaging over two to three days, long enough to build a full time-activity curve and calculate the organ and tumour doses a subsequent 90Y therapy would deliver.
It is produced on a cyclotron via 86Sr(p,n)86Y on an enriched strontium-86 target (typically SrCO3 or SrO), the preferred route because it gives the highest radionuclidic purity; the main radionuclidic impurity, 87mY, is normally kept below a few percent when highly enriched target material is used. Bombardments of a few hours at modest beam currents (2-6 microamps) are typical.
The approach was first used clinically at Forschungszentrum Jülich for pre-therapy dosimetry ahead of 90Y-citrate treatment of bone metastases, and has since been applied to 86Y-DOTA-peptide imaging ahead of 90Y-labelled somatostatin analogue therapy; it remains a research and specialist-dosimetry tool rather than a routinely stocked clinical isotope, since both the cyclotron target and the imaging protocol are non-standard.
- β+ ~33% (max 3.15 MeV)
- electron capture ~67%
- multiple γ (443-1921 keV)
- DOTA
Theranostic partners
- Yttrium-90 · A radioactive metal that fires high-energy particles a short distance into surrounding tissue. Millions of microscopic beads carrying it are injected into the artery feeding a liver tumour, where they lodge and irradiate the tumour from inside.
Similar pages
not linked directly; found by shared links- IsotopeScandium-44
Shares Chelator (bifunctional chelating agent), Theranostic pair, Radioligand dosimetry, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211) and the tag positron emitter.
- IsotopeCopper-64
Shares Albumin-binder ligands, Chelator (bifunctional chelating agent), Theranostic pair, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211) and the tags positron emitter, theranostic pair.
- IsotopeIodine-124
Shares Radioligand dosimetry, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), PET (positron emission tomography) and the tag positron emitter.
- IsotopeGallium-68
Shares Chelator (bifunctional chelating agent), Theranostic pair, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), PET (positron emission tomography) and the tags positron emitter, theranostic pair.
- IsotopeOxygen-15
Shares Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), PET (positron emission tomography) and the tag positron emitter.
- IsotopeNitrogen-13
Shares Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), PET (positron emission tomography) and the tag positron emitter.
- IsotopeCarbon-11
Shares Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211), PET (positron emission tomography) and the tag positron emitter.
- TechnologyDOTA chelation
Shares Albumin-binder ligands, Radioligand dosimetry, Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211).